NCT05836909 is a NA clinical trial of Swisse plus cholesterol capsule in Hypercholesterolemia, sponsored by Lili Yang.

Who is sponsoring NCT05836909?

NCT05836909 is sponsored by Lili Yang.

What drugs are being tested in NCT05836909?

Interventions in NCT05836909: Swisse plus cholesterol capsule, Placebo.

What condition does NCT05836909 study?

NCT05836909 studies Hypercholesterolemia.

Is NCT05836909 still recruiting?

NCT05836909 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05836909

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regulation of Lipid Metabolism in Guangzhou Individuals With Dyslipidemia by Red Yeast Rice, Phytosterol Esters and Lycopene

Status unknown NA Last updated 18 June 2023

What this trial tests

NA trial testing Swisse plus cholesterol capsule in Hypercholesterolemia in 80 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
31 October 2023

30 April 2024

Quick facts

Lead sponsor	Lili Yang
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	80
Start date	1 May 2023
Primary completion	31 October 2023
Estimated completion	30 April 2024
Sites	1 location across China

Drugs / interventions tested

Swisse plus cholesterol capsule
Placebo

Conditions studied

Hypercholesterolemia — all drugs for Hypercholesterolemia →

Sponsor

Lili Yang

Who can join

Adults 30 to 50, any sex, with Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the effect of using red yeast rice, phytosterol esters and lycopene in combination for 12 weeks on improving the glycolipid metabolism of Guangzhou individuals with dyslipidemia. Our hypothesis is that when compared with placebo, red yeast rice, phytosterol esters and lycopene together as supplements would lead to greater improvements in lipid metabolism (including lipid profiles and parameters ) in participants after 12 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07295327 — Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia · NA · recruiting
NCT06568601 — Pharmacogenomic Informed Statin Prescribing · NA · recruiting
NCT06423365 — A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication. · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05836909 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lili Yang
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05836909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing